Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dezaki, K.
Right arrow Articles by Yada, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dezaki, K.
Right arrow Articles by Yada, T.
Social Bookmarking
 Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Diabetes 53:3142-3151, 2004
© 2004 by the American Diabetes Association, Inc.

Endogenous Ghrelin in Pancreatic Islets Restricts Insulin Release by Attenuating Ca2+ Signaling in ß-Cells

Implication in the Glycemic Control in Rodents

Katsuya Dezaki1, Hiroshi Hosoda2, Masafumi Kakei3, Suzuko Hashiguchi1,4, Masatomo Watanabe1, Kenji Kangawa2, and Toshihiko Yada1

1 Department of Physiology, Division of Integrative Physiology, Jichi Medical School, Kawachi, Tochigi, Japan
2 Department of Biochemistry, National Cardiovascular Center Research Institute, Osaka, Japan
3 Department of Internal Medicine, Division of Endocrinology, Diabetes Geriatric Medicine, Akita University School of Medicine, Akita, Japan
4 Second Department of Internal Medicine, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan

Ghrelin, isolated from the human and rat stomach, is the endogenous ligand for the growth hormone (GH) secretagogue receptor, which is expressed in a variety of tissues, including the pancreatic islets. It has been shown that low plasma ghrelin levels correlates with elevated fasting insulin levels and type 2 diabetes. Here we show a physiological role of endogenous ghrelin in the regulation of insulin release and blood glucose in rodents. Acylated ghrelin, the active form of the peptide, was detected in the pancreatic islets. Counteraction of endogenous ghrelin by intraperitoneal injection of specific GH secretagogue receptor antagonists markedly lowered fasting glucose concentrations, attenuated plasma glucose elevation, and enhanced insulin responses during the glucose tolerance test (GTT). Conversely, intraperitoneal exogenous ghrelin GH-independently elevated fasting glucose concentrations, enhanced plasma glucose elevation, and attenuated insulin responses during GTT. Neither GH secretagogue receptor antagonist nor ghrelin affected the profiles of the insulin tolerance test. In isolated islets, GH secretagogue receptor blockade and antiserum against acylated ghrelin markedly enhanced glucose-induced increases in insulin release and intracellular Ca2+ concentration ([Ca2+]i), whereas ghrelin at a relatively high concentration (10 nmol/l) suppressed insulin release. In single ß-cells, ghrelin attenuated glucose-induced first-phase and oscillatory [Ca2+]i increases via the GH secretagogue receptor and in a pertussis toxin-sensitive manner. Ghrelin also increased tetraethylammonium-sensitive delayed outward K+ currents in single ß-cells. These findings reveal that endogenous ghrelin in islets acts on ß-cells to restrict glucose-induced insulin release at least partly via attenuation of Ca2+ signaling, and that this insulinostatic action may be implicated in the upward control of blood glucose. This function of ghrelin, together with inducing GH release and feeding, suggests that ghrelin underlies the integrative regulation of energy homeostasis.


Address correspondence and reprint requests to Toshihiko Yada, Department of Physiology, Division of Integrative Physiology, Jichi Medical School, Yakushiji 3311-1, Minamikawachi, Kawachi, Tochigi 329-0498, Japan. E-mail: tyada{at}jichi.ac.jp


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
DiabetesHome page
S. T. Ruohonen, U. Pesonen, N. Moritz, K. Kaipio, M. Roytta, M. Koulu, and E. Savontaus
Transgenic Mice Overexpressing Neuropeptide Y in Noradrenergic Neurons: A Novel Model of Increased Adiposity and Impaired Glucose Tolerance
Diabetes, June 1, 2008; 57(6): 1517 - 1525.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
W. P. Esler, J. Rudolph, T. H. Claus, W. Tang, N. Barucci, S.-E. Brown, W. Bullock, M. Daly, L. DeCarr, Y. Li, et al.
Small-Molecule Ghrelin Receptor Antagonists Improve Glucose Tolerance, Suppress Appetite, and Promote Weight Loss
Endocrinology, November 1, 2007; 148(11): 5175 - 5185.
[Abstract] [Full Text] [PDF]


Home page
J EndocrinolHome page
H. Takahashi, Y. Kurose, M. Sakaida, Y. Suzuki, S. Kobayashi, T. Sugino, M. Kojima, K. Kangawa, Y. Hasegawa, and Y. Terashima
Ghrelin differentially modulates glucose-induced insulin secretion according to feeding status in sheep
J. Endocrinol., September 1, 2007; 194(3): 621 - 625.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
K. Dezaki, M. Kakei, and T. Yada
Ghrelin Uses G{alpha}i2 and Activates Voltage-Dependent K+ Channels to Attenuate Glucose-Induced Ca2+ Signaling and Insulin Release in Islet {beta}-Cells: Novel Signal Transduction of Ghrelin
Diabetes, September 1, 2007; 56(9): 2319 - 2327.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
C. Gauna, R. M. Kiewiet, J. A. M. J. L. Janssen, B. van de Zande, P. J. D. Delhanty, E. Ghigo, L. J. Hofland, A. P. N. Themmen, and A. J. van der Lely
Unacylated ghrelin acts as a potent insulin secretagogue in glucose-stimulated conditions
Am J Physiol Endocrinol Metab, September 1, 2007; 293(3): E697 - E704.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
D. Kohno, M. Nakata, F. Maekawa, K. Fujiwara, Y. Maejima, M. Kuramochi, T. Shimazaki, H. Okano, T. Onaka, and T. Yada
Leptin Suppresses Ghrelin-Induced Activation of Neuropeptide Y Neurons in the Arcuate Nucleus via Phosphatidylinositol 3-Kinase- and Phosphodiesterase 3-Mediated Pathway
Endocrinology, May 1, 2007; 148(5): 2251 - 2263.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
P. Pissios, U. Ozcan, E. Kokkotou, T. Okada, C. W. Liew, S. Liu, J. N. Peters, G. Dahlgren, J. Karamchandani, Y. C. Kudva, et al.
Melanin Concentrating Hormone Is a Novel Regulator of Islet Function and Growth
Diabetes, February 1, 2007; 56(2): 311 - 319.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
R. Granata, F. Settanni, L. Biancone, L. Trovato, R. Nano, F. Bertuzzi, S. Destefanis, M. Annunziata, M. Martinetti, F. Catapano, et al.
Acylated and Unacylated Ghrelin Promote Proliferation and Inhibit Apoptosis of Pancreatic {beta}-Cells and Human Islets: Involvement of 3',5'-Cyclic Adenosine Monophosphate/Protein Kinase A, Extracellular Signal-Regulated Kinase 1/2, and Phosphatidyl Inositol 3-Kinase/Akt Signaling
Endocrinology, February 1, 2007; 148(2): 512 - 529.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
X. Zhu, Y. Cao, K. Voodg, and D. F. Steiner
On the Processing of Proghrelin to Ghrelin
J. Biol. Chem., December 15, 2006; 281(50): 38867 - 38870.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
K. Dezaki, H. Sone, M. Koizumi, M. Nakata, M. Kakei, H. Nagai, H. Hosoda, K. Kangawa, and T. Yada
Blockade of Pancreatic Islet-Derived Ghrelin Enhances Insulin Secretion to Prevent High-Fat Diet-Induced Glucose Intolerance
Diabetes, December 1, 2006; 55(12): 3486 - 3493.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
P. Marzullo, A. Caumo, G. Savia, B. Verti, G. E. Walker, S. Maestrini, A. Tagliaferri, A. M. Di Blasio, and A. Liuzzi
Predictors of Postabsorptive Ghrelin Secretion after Intake of Different Macronutrients
J. Clin. Endocrinol. Metab., October 1, 2006; 91(10): 4124 - 4130.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
J. M. Zigman and J. K. Elmquist
In search of an effective obesity treatment: A shot in the dark or a shot in the arm?
PNAS, August 29, 2006; 103(35): 12961 - 12962.
[Full Text] [PDF]


Home page
Eur J EndocrinolHome page
M. Suematsu, A. Katsuki, Y. Sumida, E. C Gabazza, S. Murashima, K. Matsumoto, N. Kitagawa, H. Akatsuka, Y. Hori, K. Nakatani, et al.
Decreased circulating levels of active ghrelin are associated with increased oxidative stress in obese subjects
Eur. J. Endocrinol., September 1, 2005; 153(3): 403 - 407.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2004 by the American Diabetes Association.